Tumour model

L1210

Lymphocytic leukemia
SyngeneicIn vitro

Standard of Care sensibility: Anti-PD1 = no / Anti PDL1 = no (12,5 mg/kg)

L1210 Cells

Mouse L1210 cells were isolated from a mouse skin tumor.

Tumor Growth In Vivo

The cells were collected from a tissue culture flask and injected intraperitoneally in B6D2F1 mice.
The resulting tumors were monitored by weighing the mice.
The mice bearing L1210 tumors can be treated by intraperitoneal, intravenous, intratumoral, or subcutaneous injection of the compounds. Oral administration is also possible.

Figure 1: (View PDF)

Tumor growth curve of the L1210 cells as ascites tumors.

  • % of weight gain
  • Mean ± SEM (n=8; take rate 100%).

Figure 2: (View PDF)

Kaplan-Meier curve for mice implanted with the L1210 tumor model.
(n=8; take rate 100%).

Drug Responses

  • Anti-PD1 (12.5 mg/kg) → No response
  • Anti-PDL1 (12.5 mg/kg) → No response

 

Download the PDF 

Model characteristics

Organism
Mouse
Tissue of origin
Lymphatic system
Pathology
Lymphocytic leukemia
Model type
In vitro, Syngeneic
Availability
Off the shelf (time of expansion)

Request this model

Tell us about your compound and your endpoints. Our team confirms feasibility, timelines and study design before any commitment.

Related models

Other models sharing the same tissue of origin.

Model
Organism
Tissue of origin
Pathology
Type
Human
Lymphatic system
B-cell Non-Hodgkin-Lymphoma
XenograftIn vitro
Human
Lymphatic system
Mantle cells lymphoma
XenograftIn vitro
Human
Lymphatic system
Lung adenocarcinoma
XenograftIn vitro
Mouse
Lymphatic system
Lymphoma
SyngeneicIn vitro
Human
Lymphatic system
Lung adenocarcinoma
XenograftIn vitro
Human
Lymphatic system
Burkitt lymphoma
XenograftIn vitro